scholarly journals Is there a place for mesenchymal stromal cell-based therapies in the therapeutic armamentarium against COVID-19?

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Kátia Nunes da Silva ◽  
André Luiz Nunes Gobatto ◽  
Zaquer Suzana Munhoz Costa-Ferro ◽  
Bruno Raphael Ribeiro Cavalcante ◽  
Alex Cleber Improta Caria ◽  
...  
Keyword(s):  
Multiple Organ ◽  
The Novel ◽  
Systemic Complications ◽  
Medical Needs ◽  
Potential Efficacy ◽  
Global Spread ◽  
Challenges And Opportunities ◽  
One Year ◽  
Novel Coronavirus ◽  
Unmet Medical Needs

AbstractThe COVID-19 pandemic, caused by the rapid global spread of the novel coronavirus (SARS-CoV-2), has caused healthcare systems to collapse and led to hundreds of thousands of deaths. The clinical spectrum of COVID-19 is not only limited to local pneumonia but also represents multiple organ involvement, with potential for systemic complications. One year after the pandemic, pathophysiological knowledge has evolved, and many therapeutic advances have occurred, but mortality rates are still elevated in severe/critical COVID-19 cases. Mesenchymal stromal cells (MSCs) can exert immunomodulatory, antiviral, and pro-regenerative paracrine/endocrine actions and are therefore promising candidates for MSC-based therapies. In this review, we discuss the rationale for MSC-based therapies based on currently available preclinical and clinical evidence of safety, potential efficacy, and mechanisms of action. Finally, we present a critical analysis of the risks, limitations, challenges, and opportunities that place MSC-based products as a therapeutic strategy that may complement the current arsenal against COVID-19 and reduce the pandemic’s unmet medical needs.

scholarly journals Hemodynamic Dysfunctions in COVID-19 Patients

2021 ◽  
Vol 10 (12) ◽  
pp. e111101220323
Author(s):  
Rubens Barbosa Rezende
Keyword(s):  
Controlled Trial ◽  
Meta Analysis ◽  
Experimental Studies ◽  
Multiple Organ ◽  
The Novel ◽  
Inclusion Criteria ◽  
Randomized Controlled ◽  
Main Target ◽  
One Year ◽  
Novel Coronavirus

Coronavirus disease 2019 (COVID-19) is a respiratory viral infection caused by the novel coronavirus (SARS-CoV-2). Thus, it objected to comprehend the pathophysiology of COVID-19, as well as its clinical repercussions on hemodynamic alterations. This is an integrative literature review, such a method is able to select and include experimental and non-experimental studies, qualitative in nature, descriptive and exploratory in character. Initially, it started from the guiding question: "What hemodynamic dysfunctions can the positive COVID-19 patient develop?" The study was conducted by searching the database: PUBMED, using the descriptors: "coagulopathy" and "COVID-19", combined by the Boolean operator AND. As inclusion criteria, the filters of one-year version, full text, clinical trial, meta-analysis, and randomized controlled trial were chosen. Coagulopathy and thromboembolic events are manifestations of COVID-19 and are designated as poor prognostic factors. The respiratory system is the main target of SARS-CoV-2, but other body systems may also be involved. Therefore, symptoms can range from respiratory distress to multiple organ failure. It is concluded that the presence of coagulopathy is a major source of mortality in COVID-19 positive patients. Also, coagulopathy is linked to the severity of the symptomatology of COVID-19, and that in more severe cases relatively increased levels of D-dimer, prothrombin time, and fibrinogen are present. In addition, no significant minimization in platelet levels was observed in severe cases of COVID-19.

scholarly journals Cutaneous presentation of COVID-19 Case Report

2020 ◽  
Vol 3 (3) ◽  
pp. 01-02
Author(s):  
Khadiga Ismail
Keyword(s):  
Public Health Emergency ◽  
World Health ◽  
The Novel ◽  
Scientific Journals ◽  
Global Public Health ◽  
The World ◽  
Global Spread ◽  
Novel Coronavirus ◽  
Health Organization ◽  
Recent Attention

COVID-19 has high transmissibility and infectivity among human. On January 30, 2020, the World Health Organization (WHO) in an effort to slow down the global spread of the virus declared the outbreak, “A global public health emergency of international concern". The skin manifestations of the novel coronavirus COVID-19 were not recognized at the early stages of the pandemic but have received much recent attention in scientific journals. Reported manifestations range from pseudo-chilblains to a morbilliform (measles-like) exanthem, urticaria, vesicular eruptions, a dengue-like petechial rash and ovate scaling macules, and plaques mimicking pityriasis rosea.

scholarly journals The New Paradigms in Clinical Research: From Early Access Programs to the Novel Therapeutic Approaches for Unmet Medical Needs

2019 ◽  
Vol 10 ◽  
Author(s):  
Cristina Scavone ◽  
Gabriella di Mauro ◽  
Annamaria Mascolo ◽  
Liberato Berrino ◽  
Francesco Rossi ◽  
...  
Keyword(s):  
Clinical Research ◽  
The Novel ◽  
Therapeutic Approaches ◽  
Medical Needs ◽  
Early Access ◽  
Unmet Medical Needs ◽  
Novel Therapeutic ◽  
Access Programs

scholarly journals POTENTIAL THERAPIES FOR TREATMENT OF COVID-19

2020 ◽  
Vol 7 (1) ◽  
pp. 062-071
Author(s):  
Beatriz Gasser ◽  
Ricardo Andres Ramirez Uscategui
Keyword(s):  
Clinical Trials ◽  
Distress Syndrome ◽  
Multiple Organ ◽  
The Novel ◽  
Controlled Clinical Trials ◽  
Interferon Β ◽  
The World ◽  
Novel Coronavirus ◽  
Time Point

Since discovery of the novel coronavirus (SARS-CoV-2) in December of 2019, this viral pneumonia originated in Wuhan, China quickly spread around the world. This new disease, called COVID-19 can cause Acute Respiratory Distress Syndrome (ARDS) due to an uncontrolled inflammatory response like sepsis, that leads to multiple organ failure and even death. Several pharmacotherapeutics alternatives are being tested over the world, looking for most diverse drugs that might be able to fight the infection. The objective of this paper is to review the main pharmacotherapeutics techniques development, as remdesivir, chloroquine/hydroxychloroquine, lopinavir plus ritonavir, interferon-β, ivermectin, anticoagulants, convalescent plasma and vaccine, currently undergoing clinical trials in order to evaluate its effectiveness and safety to combat the COVID-19, presenting their characteristics, possible adverse effects and main scientific findings of its potential action. In conclusion, some therapies presented promising in-vitro results or in the treatment of some patients, nonetheless, multicentric blinded placebo controlled clinical trials are necessary to determine their effectiveness, safety, dosage, and best time point of treatment.

scholarly journals Pharmacotherapeutic approach toward urological medications and vaccination during COVID-19: a narrative review

2021 ◽  
Vol 13 ◽  
pp. 175628722110467
Author(s):  
Mojtaba Shafiekhani ◽  
Anahita Dehghani ◽  
Mina Shahisavandi ◽  
Seyed Ali Nabavizadeh ◽  
Maryam Kabiri ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Kidney Transplantation ◽  
Prostatic Hyperplasia ◽  
Narrative Review ◽  
The Novel ◽  
Urologic Diseases ◽  
One Year ◽  
Novel Coronavirus ◽  
Comprehensive Study

One year after the prevalence of the novel coronavirus pandemic, some aspects of the physiopathology, treatment and progression of coronavirus 2019 disease (COVID-19) have remained unknown. Since no comprehensive study on the use of urological medications in patients with COVID-19 has been carried out, this narrative review aimed to focus on clinically important issues about the treatment of COVID-19 and urologic medications regarding efficacy, modifications, side effects and interactions in different urologic diseases. In this review, we provide information about the pharmacotherapeutic approach toward urologic medications in patients with COVID-19 infection. This study provides an overview of medications in benign prostatic hyperplasia, prostate cancer, impotence and sexual dysfunction, urolithiasis, kidney transplantation and hypertension as the most frequent diseases in which the patients are on long-term medications. Also, the effect of urologic drugs on the efficacy of vaccination is briefly discussed.

scholarly journals THE INFLUENCE OF CHRONIC DISEASES ON THE MANIFESTATION OF COVID-19 INFECTION

2021 ◽  
pp. 126-132
Author(s):  
S. O. Yastremska ◽  
O. M. Krekhovska-Lepiavko ◽  
B. A. Lokay ◽  
O. V. Bushtynska ◽  
S. V. Danchak
Keyword(s):  
Chronic Diseases ◽  
Case Fatality ◽  
The Novel ◽  
Fatality Rate ◽  
The World ◽  
Control And Prevention ◽  
The Usa ◽  
Life Threatening ◽  
One Year ◽  
Novel Coronavirus

Summary. The first known case of infection from the novel coronavirus was recorded almost one year ago, in China’s Hubei province. The city of Wuhan was infamous the world over as the original virus epicenter, seeing more than half of China’s reported cases and deaths. The outbreak of COVID-19 virus, as sickened more than 14.7 million people. At least 610.200 people have died. The aim of the study – to analyze and systematize the literature data about the influence of chronic diseases on the manifestation of COVID-19 infection. Materials and Methods. The study uses publications of the world scientific literature on COVID-19 infection, in particular the causes and mechanisms of its development, treatment, complications and its consequences as well as the influence of different chronic disorders on the course of COVID-19. Results. A sample of patients hospitalized with COVID-19 across 14 states of the USA in March was analyzed by The Centers for Disease Control and Prevention. It was found that many (89 %) had underlying health problem and 94 % of patients were at the age 65 and older. The case fatality rate for those under age 60 was 1.4 percent. For those over age 60, the fatality rate jumps to 4.5 percent. The older the population, the higher the fatality rate. For those 80 and over, Covid-19 appears to have a 13.4 percent fatality rate. Moreover, it was recognized, that older adults don't present in a typical way of the course of different disorders, and we're seeing that with Covid-19 as well. Conclusions. Chronic diseases and conditions are on the rise worldwide. COVID-19 became the most challenging pandemic influencing all countries worldwide. Chronic diseases are suggested to be one of the main causes of different life-threatening complications of COVID-19 infection and one of the main factors of poor prognosis for the patients.

scholarly journals The Information Infrastructure of Search Engines: A Content Analysis of Covid-19 Immunization Information Online

2021 ◽  
Vol 6 (2) ◽  
Author(s):  
Renée Belliveau
Keyword(s):  
Content Analysis ◽  
Search Engines ◽  
World Health ◽  
The Novel ◽  
Online Search ◽  
Global Pandemic ◽  
The World ◽  
Global Spread ◽  
Novel Coronavirus ◽  
Health Organization

After the World Health Organization declared the spread of the novel coronavirus (COVID-19) a global pandemic in March 2020, they cautioned of another outbreak: an “infodemic.” This study examines how online search engines are influencing the global spread of immunization information about COVID-19. It aims to address the various ways in which search technology is shaping users’ perceptions of the pandemic and to measure the credibility of the sources they provide.

scholarly journals Kidney damage by COVID-19 and rationale for extracorporeal therapies

2020 ◽  
Vol 7 (10) ◽  
pp. 4071-4074
Author(s):  
Uzma Mehreen ◽  
Ashiq Ali ◽  
Aisha Khatoon ◽  
Nishat Zafar ◽  
Qaisar Tanveer ◽  
...  
Keyword(s):  
Human Body ◽  
Multiple Organ ◽  
Blood Purification ◽  
Kidney Damage ◽  
The Novel ◽  
Kidney Involvement ◽  
Novel Coronavirus ◽  
Extracorporeal Support ◽  
Organ Dysfunctions

Without doubt, there is some involvement of the kidney in novel coronavirus disease (COVID-19), which is responsible for multiple organ dysfunctions resulting in severe complications in the human body. This newly discovered COVID-19 has incited panic globally. However, the role of kidney involvement in the novel COVID-19 disease is still unclear. In this commentary, we discuss the various pathways involved in kidney damage by COVID-19, and the rationale for extracorporeal support with various blood purification strategies in critically ill people with COVID 19.

scholarly journals COVID-19 quarantine: Post-traumatic stress symptomatology among Lebanese citizens

2020 ◽  
Vol 66 (7) ◽  
pp. 666-674 ◽  
Author(s):  
Mirna Fawaz ◽  
Ali Samaha
Keyword(s):  
Traumatic Stress ◽  
Cross Sectional Study ◽  
The Novel ◽  
Post Traumatic Stress ◽  
Cross Sectional ◽  
Epidemic Curve ◽  
Global Spread ◽  
Post Traumatic ◽  
The Times ◽  
Novel Coronavirus

Background: In the light of the global spread of the novel Coronavirus known as COVID-19 and in the absence of an approved treatment and vaccination, Lebanon has taken national measures, among which was home quarantine of the general public in an attempt to flatten the epidemic curve and avoid flooding the health care system. Aim: This study aimed at evaluating the prevalence of post-traumatic stress symptomatology (PTSS) during the times of COVID-19 quarantine among Lebanese citizens. Method: This quantitative cross-sectional study recruited 950 civilians and is aimed at measuring the prevalence of PTSS among the Lebanese citizens at an interval of 2 weeks and 1 month of COVID-19 quarantine. Results: The results have shown that quarantine in Lebanon has started to give rise to Post-traumatic Stress Disorder symptomatology during the second week which was worsened in the fourth week of COVID-19 quarantine. Conclusion: COVID-19 quarantine has influenced the psychology of Lebanese citizens and might have persistent effects after the end of this phase which is recommended to be explored.

scholarly journals Pathogenesis, Diagnosis, and Treatment of Hemostatic Disorders in COVID-19 Patients

Acta Naturae ◽  
2021 ◽  
Vol 13 (2) ◽  
pp. 79-84
Author(s):  
Airat F. Khalirakhmanov ◽  
Kamilla F. Idrisova ◽  
Raushaniya F. Gajfullina ◽  
Sergey V. Zinchenko ◽  
Rustem I. Litvinov ◽  
...  
Keyword(s):  
Multiple Organ ◽  
Pulmonary Insufficiency ◽  
The Novel ◽  
Thromboembolic Complications ◽  
Short Period ◽  
Prevention And Treatment ◽  
Organ Failures ◽  
Coronavirus Infection ◽  
Novel Coronavirus ◽  
Hemostatic Disorders

The novel coronavirus infection named COVID-19 was first detected in Wuhan, China, in December 2019, and it has been responsible for significant morbidity and mortality in scores of countries. At the time this article was being written, the number of infected and deceased patients continued to grow worldwide. Most patients with severe forms of the disease suffer from pneumonia and pulmonary insufficiency; in many cases, the disease is generalized and causes multiple organ failures and a dysfunction of physiological systems. One of the most serious and prognostically ominous complications from COVID-19 is coagulopathy, in particular, decompensated hypercoagulability with the risk of developing disseminated intravascular coagulation. In most cases, local and diffuse macro- and microthromboses are present, a condition which causes multiple-organ failure and thromboembolic complications. The causes and pathogenic mechanisms of coagulopathy in COVID-19 remain largely unclear, but they are associated with systemic inflammation, including the so-called cytokine storm. Despite the relatively short period of the ongoing pandemic, laboratory signs of serious hemostatic disorders have been identified and measures for specific prevention and correction of thrombosis have been developed. This review discusses the causes of COVID-19 coagulopathies and the associated complications, as well as possible approaches to their early diagnosis, prevention, and treatment.

Sign in / Sign up

Export Citation Format

Share Document